drugset / Trial / NCT00908154

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

NCT00908154

Phase 1 Completed 51 enrolled Biogen
RandomizedSingle-groupDouble-blindTreatment

Summary

GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models. This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses of GSK1014802 administered for up to 28 days in healthy male or female subjects. In addition, the effect of food on the pharmacokinetics of GSK1014802 will be investigated.

Timeline

Start
2008-05-31
Primary completion
2008-12-31
Completion
2008-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Vixotrigine Small molecule

Indications